Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674665 | 1.00 | KDM1A (0.56) | KDM1AMAOBMAOATHRATHRB | |
| SCHEMBL8252175 | 0.91 | THRB (0.58) | KDM1AMAOBMAOATHRATHRB | |
| SCHEMBL15729561 | 0.87 | MAPT (0.57) | KDM1AMAOBMAOATHRATHRB | |
| SCHEMBL25430974 | 0.84 | THRB (0.48) | KDM1AMAOBMAOATHRATHRB | |
| SCHEMBL15729804 | 0.81 | THRA (0.49) | KDM1AMAOBMAOATHRATHRB | |
| SCHEMBL9321924 | 0.81 | THRB (0.46) | KDM1AMAOBMAOATHRATHRB | |
| SCHEMBL1017228 | 0.81 | KDM1A (0.54) | KDM1AMAOBMAOATHRATHRB | |
| SCHEMBL3920253 | 0.80 | KDM1A (0.59) | KDM1AMAOBMAOAMAPTGAA | |
| SCHEMBL30259750 | 0.80 | KDM1A (0.56) | KDM1AMAOBMAOATHRATHRB | |
| SCHEMBL27901340 | 0.80 | KDM1A (0.59) | KDM1AMAOBMAOAHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-06-05 | — | — | US | disclosed |
| CN-105980392-A | Bromodomain inhibitors | 艾伯维公司 | 2016-09-28 | — | — | CN | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | KDM1A 1508/4885MAOB 1465/4885MAOA 1356/4885 |
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ESR1, ESR2, ESRRA | KDM1A 701/4885MAOB 1173/4885MAOA 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.